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Abstract
Background: Chronic spontaneous urticaria (csU), which is characterized by recurrent episodes of mast cell-driven wheal
and flare-type skin reactions, is often associated with elevated total IgE levels and thyroid autoimmunity. We speculate that
some csU patients express IgE autoantibodies against thyroid antigens such as thyroid peroxidase (TPO), which could bind
to skin mast cells and induce their activation.
Methods: We developed and used a site-directed human IgE capture ELISA to quantify IgE-anti-TPO. We used this assay and
investigated csU patients (n=478) and healthy control subjects (n=127) for IgE-anti-TPO and then assessed IgE-anti-TPO-
positive and -negative csU patients for clinical and serological differences.
Principal Findings: CsU patients were found to express more than 2fold higher IgE-anti-TPO serum levels as compared to
healthy control subjects (p,0.001). 54% of csU patients had serum levels higher than the cut off (=5 IU/ml). By distribution
analyses we identified two distinct subpopulations of csU patients: 1) IgE-anti-TPO
low (=39%, IgE-anti-TPO: median 2.17
interquartile range 0.86–5.44, = comparable to healthy controls) and 2) IgE-anti-TPO
high (=61%, IgE-anti-TPO: median 6.67,
interquartile range 5.39–8.24). IgE-anti-TPO-positive and -negative csU patients had very similar distributions of age and
gender as well as disease activity and duration. IgE-anti-TPO-positive csU patients exhibited significantly higher IgG-anti-
TPO levels and lymphocyte counts as well as decreased C4 complement levels.
Conclusion: Our findings show that a sizeable subgroup of csU patients expresses IgE antibodies against thyroid
peroxidase. These autoantibodies could cause ‘‘autoallergic’’ mast cell activation, a novel pathomechanism of chronic
spontaneous urticaria.
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Introduction
Urticaria is a common condition characterized by itchy wheal
and flare type skin reactions (hives) and/or angioedema [1]. These
symptoms are brought about by activated skin mast cells and their
subsequent release of histamine and other proinflammatory
mediators [2]. The underlying causes and the mechanisms of
mast cell activation in most types of urticaria are largely unknown
and remain to be identified.
Based on clinical observations, several pathways of mast cell
activation in urticaria have been proposed. For example, patients
with chronic spontaneous urticaria (csU), the most frequent type of
non acute urticaria, have repeatedly been described to exhibit
increased levels of IgE. In a recent study, 50% of csU patients
exhibited significantly (i.e. more than 4fold) elevated levels of total
serum IgE (.100 IU/ml) as compared to only 13% of healthy
control subjects [3]. This raises the possibility that in csU mast cells
may be activated by allergens that engage specific IgE antibodies
bound to their high affinity IgE receptor, FcepsilonRI. However,
sensitisations to aeroallergens or other environmental allergens,
even uncommon ones, are rarely found to be the cause of csU
[3, 4].
Also, csU patients have been reported to frequently suffer from
autoimmune conditions, especially thyroid autoimmune disorders
such as Hashimoto’s thyroiditis [5, 6]. Several independent studies
have demonstrated that a significant number of csU patients (in
some studies up to 33%) exhibit high levels of autoantibodies to
thyroid antigens [7]. As of now, a role of thyroid autoimmunity
and thyroid antibodies in mast cell activation in csU remains to be
proven.
Here, we postulate that skin mast cells in some csU patients are
activated by an ‘autoallergic’ mechanism. Specifically, we
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e14794speculate that patients with thyroid autoimmunity and IgG
autoantibodies to thyroid antigens can also exhibit IgE autoanti-
bodies to these autoantigens that then function as ‘autoallergens’.
To test our hypothesis, we have developed an ELISA-based
detection assay for IgE antibodies to thyroid peroxidase (TPO) and
we have tested csU patients and healthy subjects for the presence
of these IgE autoantibodies to TPO (IgE-anti-TPO).
Results
Chronic spontaneous urticaria patients exhibit elevated
levels of IgE against thyroid peroxidase (IgE-anti-TPO)
Levels of IgE-anti-TPO, as assessed by site-directed IgE capture
ELISA, were found to be significantly higher in csU patients
(median 5.50, interquartile range IQR 3.2–7.7) as compared to
healthy subjects (median 1.46, IQR 0.27–4.45 IU/ml) (Fig. 1a).
Based on the ROC analysis of these findings (Fig. 1b) we defined
5.0 IU/ml as the cut off value (specificity =0.8, Table 1) and
found that 259 of 478 csU patients (54.2%) exhibit elevated levels
of IgE-anti-TPO.
CU patients are IgE-anti-TPO
low or IgE-anti-TPO
high
The distribution of IgE-anti-TPO levels in csU patients showed
two distinct peaks, one very similar to that found in healthy
controls and a second at above cut off IgE-anti-TPO levels
(Fig. 2a). Indeed, distribution analyses of IgE-anti-TPO levels in
csU patients showed two distinct subpopulations, i.e. the observed
distribution of IgE-anti-TPO levels in csU patients resembled a
mixture of two normal distributions with different means and
different standard deviations (IgE-anti-TPO
low and IgE-anti-
TPO
high patients). IgE-anti-TPO
low csU patients (39% of all csU
patients) exhibited IgE-anti-TPO levels that were very similar to
those of healthy controls (median 2.17 IQR 0.86–5.44 IU/ml). In
contrast, the median level in IgE-anti-TPO
high patients (61% of all
csU patients) was 6.67 (IQR 5.39–8.24 IU/ml (Fig. 2b). This two
population model was highly significant as compared to a one
component model (p,0.001). The theoretical ROC curve is
presented in figure 2b.
Levels of autoantibodies and lymphocytes are high and
complement levels are low in csU patients with elevated
IgE-anti-TPO
CsU patients with above cut off IgE-anti-TPO levels (IgE-anti-
TPO+) were indistinguishable from those with below cut off levels
(IgE-anti-TPO–) in terms of age, gender ratio, duration or severity
of disease and total IgE serum levels. There also was no significant
difference of the rates of ASST positive patients between the two
patient populations, although the IgE-anti-TPO+ patients were
largely ASST negative (Table 2). In contrast, IgE-anti-TPO+
patients showed significantly higher levels of IgG-anti-TPO as well
as lymphocyte numbers and lower levels of complement C4 as
compared to IgE-anti-TPO– csU patients (Table 3).
Discussion
Here, we show for the first time that a sizeablesubgroup of patients
with chronic spontaneous urticaria exhibits IgE antibodies against
self, i.e. against thyroid peroxidase. These IgE-anti-TPO autoanti-
bodies, when bound and activated on the surface of mast cells, could
cause ‘autoallergic’ mast cell degranulation, a novel pathogenic
pathway of urticaria induction. We used the method of univariate
mixture analysis to analyse the dependence between IgE-anti-TPO
and CsU. This method is useful to detect and to explain heterogeneity
in data. It should be mentioned, however, that the interpretation of
mixture components as subpopulations is only one possible option.
Mast cell activation in csU has repeatedly been shown to involve
autoantibodies, for example, IgG autoantibodies directed against
Figure 1. Patients with chronic spontaneous urticaria exhibit elevated levels of IgE-anti-TPO. Fig. 1a Box-Plot: Healthy persons (n=127)
exhibit in the mean IgE-anti-TPO levels of 2.58 IU/ml62.46, 1st quartile 0.27– median 1.46– 3rd quartile 4.45 (median 1.46, IQR 0.27–4.45 IU/ml).
Highest value among the healthy persons was 7.8 IU/ml. CU patients (n=478) show elevated mean levels of 5.69 IU/ml63.17, 1st quartile 3.2–
median 5.5– 3rd quartile 7.73, (median 5.50, IQR 3.2–7.7 IU/ml), highest value 18.0 IU/ml. The differences between the two groups are statistical
significant (p,0.001). Figure 1b ROC-Curve: Diagnostic accuracy for the distinction of CU patients and healthy controls was analysed by ROC curve
including selected pairs of sensitivity and specificity (Table 1), the area under the curve (AUROC=0.78) and the confidence limits for this curve
(CI=0.74–0.83). The selected specificity of 0.8 and the resulting sensitivity of 0.55 are displayed as dotted line in the graph.
doi:10.1371/journal.pone.0014794.g001
Table 1. Cut-off values, sensitivities and specificities for IgE-
anti-TPO.
Cut-Off (IU/ml) 1.20 1.80 2.30 2.70 3.20 3.60 4.10 4.60 5.00 5.50 6.40
Sensitivity 0.95 0.90 0.85 0.80 0.75 0.70 0.65 0.60 0.55 0.50 0.42
Specificity 0.49 051 0.53 0.54 0.56 0.62 0.70 0.78 0.80 0.86 0.90
doi:10.1371/journal.pone.0014794.t001
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autoantibodies can be detected in 24% to 60% of csU patients
[10–12] and they have been shown to be relevant in patients with
autoreactive csU, i.e. csU patients that are positive in the
autologous serum skin test (ASST) [12,13]. In contrast, IgE
autoantibodies, such as those detected in about 50% of csU
patients in our study, have not been described as relevant for the
activation of mast cells in csU, except for in single patients. Ten
years ago, Bar Sela and coworkers were able to detect such
antibodies in the serum of a female patient who suffered from csU
and Hashimoto’s thyroiditis [14]. Subsequent studies using classic
ELISA or RAST were unable to reproduce these findings in
patients with csU and thyroid autoimmunity [15], probably due to
interfering IgG autoantibodies [16] and the limited sensitivity of
these assays. We were able to detect IgE specific for TPO by
classical ELISA (Supplemental Figure S1b). Only after depleting
competing IgG autoantibodies from the patient serum via protein
G affinity chromatography and after removing all minor proteins
by centrifugal ultrafiltration (Supplemental Figure S1c). In
contrast, the new human-IgE-capturing-enzyme immunoassay
developed and used in the present study allows for the detection of
IgE-autoantibodies specific to TPO without prior depletion of IgG
antibodies. (Supplemental Figure S1a)
Autoallergic mast cell activationhasbeenimplied to play a role in
other chronic inflammatory skin disorders such as atopic dermatitis
[17,18] and bullous pemphigoid [19,20,21]. In both diseases IgE
antibodies directed to skin antigens have been described and may
play a role in the pathogenesis by activating cutaneous mast cells
after binding their corresponding skin antigen. In contrast, the IgE
autoantibodies detected in our study are directed against an
extracutaneous antigen (= autoallergen), i.e. TPO, which can be
released from the thyroid into the circulation. IgE-anti-TPO is,
therefore, likely to be bound to mast cells, basophils and other
FcepsilonRI-expressing cells throughout the body. This may explain,
why symptoms in csU patients are not limited to the skin, as in
atopic dermatitis and bullous pemphigoid, but can also involve the
gut, the airways, the joints and other organs.
For atopic dermatitis it was postulated that mimicry of protein
domains of external allergens and self-proteins may turn an allergy
against an environmental allergens into an autoallergy [22,23,24].
This is unlikely to be the case in csU, which is rarely associated with
allergies to environmental allergens. However, autoallergen mimicry
cannot be excluded in csU, as the extracellular domain of TPO has a
similarity of around 45% with myeloperoxidases from eosinophils
[25]. Also, IgE-anti-TPO production and detection may involve
peroxidases of common cutaneous pathogens, including fungi.
Figure 2. CU Patients can be divided into IgE-anti-TPO
high and IgE-anti-TPO
low subgroups. Figure 2a Density Estimation: CU patients (full
line) and healthy controls (dotted line) were clearly different regarding their IgE-anti-TPO levels. CU patients can be subdivided in two subgroups, one
similar to the healthy controls and the other one above the indicated cut off level of 5 IU/ml. Figure 2b Theoretical ROC-Curve: The theoretical ROC-
Curve shows the result of the applied method of mixed distribution to identify subgroups within the patients’ sample. This analysis was motivated by
the hypothesis that only for a subtype of the disease IgE is involved in the pathological pathway. For the resulting normal distribution of the second
subpopulation with elevated IgE-anti-TPO (IgE-anti-TPO
high) values the theoretical ROC curve is displayed.
doi:10.1371/journal.pone.0014794.g002
Table 2. Similarities and differences of IgE-anti-TPO+ and IgE-anti-TPO- CU patients.
IgE-anti-TPO+ IgE-anti-TPO- Statistical significance
Female 200 of 265 (75.5%) 166 of 213 (77.9%) n.s.
Age (years) 45.5614.5 (n=265) 47.8614.6 (n=213) n.s.
Duration of disease (years) 7.1610.4 (n=103) 5.969.7 (n=50) n.s.
UAS 2.41 (2.0 (n=17) 2.50 (1.8 (n=52) n.s.
DLQI (sum) 7.8 (5.4 (n=71) 8.9 (7.2 (n=85) n.s
Total serum IgE (IU/ml) 175,166335,74 (n=121) 221,106332,07 (n=213) n.s.
Positive ASST (% of n) 16,7 (n=30) 30,8 (n=26) n.s.
Values are given as mean 6 standard deviation, exept for ASST (given in %).
doi:10.1371/journal.pone.0014794.t002
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incidence of autoimmune thyroiditis [6,26], and up to 33% of
patients reportedly express increased IgG antibodies directed against
thyroid peroxidase or thyreoglobuline as compared to 5% in healthy
individuals [7]. Also, csU patients exhibit significantly (more than
4fold) increased levels of total serum IgE (.100 U/ml) [3]. In
contrast, relevant sensitizations against common environmental
allergens are rarely found in csU patients. These findings may be
explained, at least in part, by the results of our study: 1) IgE-anti-TPO
expression is positively correlated to IgG-anti-TPO expression. In
other words: IgG-anti-TPO-positive patients are more likely to
express potentially urticaria-inducing IgE-anti-TPO. 2) IgE-anti-
TPO may contribute to higher total IgE levels in csU patients.
With autoreactivity, intolerance, infection, and other underlying
conditions shown to be relevant causesof csU, it is unlikely that IgE-
anti-TPO is the relevant mast cell activator in all csU patients. Our
statistical analyses using the method of mixed distribution identified
2 distinct subgroups – one IgE-anti-TPO
low and the other IgE-anti-
TPO
high. This supports the theory that autoallergy is of pathological
relevance only in a subpopulation of csU patients. However, IgE
autoantibodies directed against other autoantigens may exist and
act as relevant mast cell activators in those patients shown to express
low levels of or no IgE-anti-TPO [27].
Interestingly, IgG-anti-TPO and IgE-anti-TPO are positively
correlated in IgE-anti-TPO+ but not IgE-anti-TPO- csU patients,
suggesting that IgG-anti-TPO may be a good screening marker for
the presence of IgE-anti-TPO and vice versa. Also, high IgE-anti-
TPO is correlated with increased lymphocyte counts and C4
consumption, two common features of autoimmune conditions.
There is growing consus that in a subgroup of patients csU should
be regarded as an autoimmune disease with potential upregulation
of previously unrecognized autoimmune manifestations. It needs to
be proven that these manifestations are directly related and relevant
to the pathogenesis of disease in the affected patient population.
Taken together, we can show that IgE-anti-TPO autoantibodies
are common in csU patients. These findings point towards an
autoallergic mechanism of mast cell activation as a novel and
relevant pathogenetic mechanism in csU. Our results also
encourage to screen csU patients for IgE directed against
autoantigens other than TPO and to test IgE-neutralizing
strategies such as omlizumab for their efficacy in csU.
Materials and Methods
Patients
Sera obtained from 478 consecutive csU patients treated at the
Department of Dermatology, Charite ´ – Universita ¨tsmedizin Berlin
were tested for IgE-anti-TPO levels (Table 4). As controls, sera
from 127 age- and sex-matched healthy subjects were used
(Table 4). All subjects gave written informed consent. This study
was approved by the ethics committee of the Landesa ¨rztekammer
Rheinland-Pfalz and done in accordance with the Declaration of
Helsinki.
Detection of IgE-anti-TPO. IgE-anti-TPO serum levels were
assessed by a site-directed IgE capture ELISA (depicted in
Supplemental figure S1a). To this end, serum IgE was first
captured using hydrazine surface plates (Costar Corning,
Badhoevedoerp, Netherlands) coated with site-directed Fc epsilon-
specific anti-human IgE antibodies from goat serum (Sigma-
Aldrich, Deisenhofen, Germany). After blocking with 10% FCS in
PBS, plates were incubated consecutively with serum (diluted 1:25,
for 120 minutes, at 20uC), followed by biotinylated (biotin XX-
labeling kit, Pierce, Rockford, IL, USA) recombinant human-TPO
(RSR Ltd, Cardiff, UK), streptavidine alkaline phosphatase
(1:10,000; Jackson Immunoresearch, West Grove, PA, USA), and
its substrate p-NPP (Sigma-Aldrich, Deisenhofen, Germany).
Between each step intensive washing with TBS containing
0.025% Tween 20 was performed. As a last step, the enzymatic
dye reaction was stopped with 3 M NaOH and the optical density
was measured at 405 nm using a MultiScan Ascent plate reader.
Chimaeric human IgE-anti-TPO was obtained from the
supernatant of SP-2/Sp1,4 transfected mouse myeloma cells
(kindly provided by Sandra McLachlan, Thyroid Autoimmune
Disease Unit, Cedars-Sinai Medical Center and University of
California Los Angeles) grown in 10% FCS gold IMEM-medium,
2 mM L-Glutamine, 100 U/ml Penicillin and 10 mg/ml
Streptomycin (all Sigma-Aldrich, Deisenhofen, Germany),
quantified by RAST, and used as a positive control and standard.
(Standardcurve and reproducibility see supplemental figure S2)
The detection of IgE-anti-TPO with this assay was confirmed in
selected sera by western blot (Supplemental figure S3) and/or
classical ELISA after removal of IgG via Protein-G-affinity
chromatography and of low molecular weight proteins via
ultrafiltration (Supplemental figure 1c).
Assessment of urticaria activity and serum markers for
inflammation, autoimmunity or allergy
Disease activity in all csU patients was determined by use of the
UAS7, the urticaria activity score of seven consecutive days (44, 45).
Table 3. IgE-anti-TPO+ CU patients, but not IgE-anti-TPO- CU patients, show correlations of IgE-anti-TPO with IgG-anti-TPO,
lymphocyte counts and complement C4 levels.
IgE-anti-TPO+ IgE-anti-TPO-
IgG-anti-TPO r=0.285 p=0.002 (n=113) r=0.129 p=0.327 (n=60)
Complement C4 r=20.246 p=0.006 (n=113) r=20.071 p=0.552 (n=72)
Lymphocytes r=0.208 p=0.019 (n=127) r=20.023 p=853 (n=70)
Values are given as Correlation Coefficient r (Spearman’s Rank Test).
doi:10.1371/journal.pone.0014794.t003
Table 4. Patient statistics.
CU patients Healthy controls
Number 478 127
Female (%) 72.4 76.6
Age (years) * 43.3617.0 46.5614.5
*Values are given as mean 6 standard deviation. There are no significant
differences between the two groups.
doi:10.1371/journal.pone.0014794.t004
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points, up to 20 wheals =1 point, 21 to 50 wheals or large confluent
wheals =2 points, and .50 wheals =3 points) and the severity of
pruritus (no pruritus =0 points, mild pruritus =1 point, moderate
pruritus =2 points, severe pruritus =3 points) every day during the
week before collecting blood for IgE-anti-TPO analyses (range of
UAS7 =0 points to 42 points).
Blood collected from csU patients for IgE-anti-TPO analyses
was also investigated for parameters of inflammation (erythrocyte
sedimentation rate, blood count, c-reactive peptide, serum
electrophoresis), autoimmunity (immunoglobuline levels, thyroid
autoantibodies and hormones, complement, circulating immune
complexes, rheumatoid factor, indirect immunoflourescent testing,
anti-nuclear antibodies, anti-neutrophil antibodies) and allergy
(IgE serum levels). These analyses were done by the Charite ´
central laboratory using standard assays.
Statistics
Descriptive analysis presents means and standard deviations, for
the right skewed IgE-anti-TPO measurements medians and the
interquartile range (IQR) was calculated.To achieve normal
distributions for model based analyses, log transformation was
applied if necessary. Correlations were calculated using Spear-
mans Rank Test. The diagnostic accuracy for the distinction of
csU patients and healthy controls based on their serum levels of
IgE-anti-TPO was analysed by the calculation of a ROC curve
including selected pairs of sensitivity and specificity, of the area
under the curve (AUROC), and of the confidence limits for this
curve. In addition, a density estimator for the distribution of IgE-
anti-TPO values in the healthy subjects and csU patients was
given. CsU patient subgroups with a normal distribution were
identified by the method of mixed distribution [28] and
characterized by the calculation of theoretical ROC curves. The
theoretical ROC curves are obtained by replacing observed values
of sensitivity and specificity by the theoretical values obtained from
both normal distributions.
Supporting Information
Figure S1 Differences of a classic ELISA vs. site-directed IgE
capture ELISA. Direct ELISA (Suppl. Fig. S1b) was classical
performed in Nunc Maxisorp 96 well plates. In brief the wells were
loaded with hu rec. TPO 1 mg/ml (RSR-Biochemicals Ltd. Cardiff,
UK) in a pH 9,2 100 mM Na-HCO3/Na2HPO4 buffer, followed
by blocking with 2% BSA in PBS. After washings diluted serum
(1:25) or standard TPO as calibration standard was applied for
2 hours.BoundIgEwasditected viaFc-biotinylatedgoatantihuIgE
(Sigma-Aldrich, Deisenhofen, Germany, 1:1000 in PBS) and
Streptavidin-horse radish peroxidase (Sigma-Aldrich, 1:4000 in
PBS). Enzymatic stain reaction was then started with 0,02%
hydrogen peroxide and 0,02% ABTS (2,2 `-azinodi-(3-ethylbenzthia-
zoline)-sulfonic acid) in 20 mM Na-citrate buffer at pH 5,0 and
stopped with 1% SDS in PBS after 30 min reaction time. The
reaction product was measured at 405 nm in an Ascent Multiscan
ELISA-plate reader (Thermolab Systems Oy, Turku Finland). This
classical ELISA which are usually applicable for detection of IgE
towards external antigens failed in detecting auto-IgE in relevant
CU sera, although the patients exhibited thyroid pathology and
elevated total IgE [*]. After removing the possible competing auto-
IgGantiTPOwewereabletodetectIgEanti-TPO-autoantibodyin
the same CU sera in classic sandwich ELISA as expected [16]
(Extinctions see Fig. S1c). Since large-scaled purification procedures
of patient’s sera prior to routine ELISA is uneconomic and has
difficulties with the reproducibility, we established a special site-
directed hu-IgE capture ELISA (Fig. S1b) as described in Materials
and Methods. Supplemental Figure S1c: Comparison of an classic
ELISA after IgG depletion vs. site-directed IgE capture ELISA
Immunospecific detection (optical density OD 405) of IgE-anti-
TPO in a defined CU patient’s serum by direct ELISA and after
Protein-G & anti-IgE affinity chromatography in comparison with
site-directed IgE capture ELISA. As control served standard anti-
TPO-hIgE measured via direct ELISA (direct ELISA, grey bar).
Classical direct ELISA (Fig. S1b) which is usually applicable for
detection of IgE towards external antigens failed in detecting auto-
IgE-anti-TPO probably due to competing auto-IgG-anti-TPO.
When possible competing auto-IgG was removed via Protein-G
affinity chromatography and via ultrafiltration through a MW
10000 membrane, this IgE fraction (direct ELISA, black bar)
yielded in a much better detectable signal in OD405 in classic
sandwich ELISA compared to non purified samples (direct ELISA,
white bar). In contrast, the site-directed IgE capture ELISA (Fig.
S1a), allows a highly sensitive detection of occurring auto-IgE-anti-
huTPO with the same specificity as for purified IgE samples (site-
directed IgE capture ELISA, white bar). [*] Concha LB, Chang
CC, Szema AM, Dattwyler RJ, Carlson HE (2004) IgE antithyroid
antibodies in patients with Hashimoto’s disease and chronic
urticaria. Allergy Asthma Proc 25: 293–296.
Found at: doi:10.1371/journal.pone.0014794.s001 (0.50 MB TIF)
Figure S2 Standardcurve and Reproducibility of the site-
directed IgE capture ELISA. The site-directed IgE capture ELISA
allows a highly sensitive, straight forward and reproducible
detection of auto-IgE-anti-huTPO in the sera of patients. The
site-directed IgE capture ELISA showes an almost linear
correlation of the standard IgE-anti-TPO with the extinction at
405 nm (S2a). The reproducibility of 10 consecutive measure-
ments of one CU patient with a high IgE-anti-TPO level resulted
in a coefficient of variation of 0,127. (S2b)
Found at: doi:10.1371/journal.pone.0014794.s002 (1.04 MB TIF)
Figure S3 Immunoblot of purified IgE Fractions of a CU-
Patient (A) and a healthy control (B) on microsomal thyroid
extrakts run on SDS-PAGE + WB. Proteinstaining of microsomal
thyroid extracts (C) and of purified corunning recombinant hTPO
(D). Proteins of microsomal thyroid extracts (40 mg TPO/ml) and
purified corunning recombinant hTPO were separated on
discontinuous SDS polyacrylamide gels (conc. 3%/8% acc.).
Electrophoresis was run in a Hoefer SE-260 Mighty VE-chamber
(Pharmacia GmbH, Freiburg) at 8uC, 40 mA, for 150 minutes.
Western blotting of separated proteins on 0,45 mm nitrocellulose
sheets (Schleicher & Schu ¨ll, Dassel, Germany) was performed in a
Hoefer Mini-Transfer chamber (Pharmacia GmbH, Freiburg,
Germany). Afterwards the sheets were cut in strips. One strip with
microsomal thyroid extracts (C) and one with recombinant TPO
(D) underwent an immediate staining with 0,01% Amidoblack in
10% Acetic acid, 20% MeOH, 70% water. The remaining strip
with microsomal thyroid extracts were blocked with 5% milk
powder in 150 mM NaCl, 10 mM Tris/HCl pH 8,0, 0,05%
Tween 20 (TBST) overnight at 4uC and afterwards incubated for
2 hours in separate bags with purified anti-TPO IgE (diluted 1:10
in TBST, 1%BSA) of sera taken from a CU patient (A) and health
control (B). Specific human IgE antibodies were marked by goat
anti-human IgE alkaline phosphatase conjugates (1:400 in TBST,
1%BSA) for 2 h at 25uC. Dye reaction was started with 50 ml
0,02% Nitro blue tetrazolium in 150 mM Tris/HCl pH 9,6,
100 ml 2 M MgCl2 and 20 ml 0,2% 5-Bromo-4-chloro-3-indolyl-
phoshate (BCIP). After 60 min. incubation time at 25uC the
reaction was stopped with water.
Found at: doi:10.1371/journal.pone.0014794.s003 (0.45 MB TIF)
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